Submission to first decision (The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor)
Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date.
3 weeks
Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) 6 weeks
Submission to final decision (The average time from manuscript submission to the final editorial decision) 16 weeks
Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) 24 weeks

ACTA Pharmaceutica Sciencia 2018 , Vol 56 , Num 1
Estimation of Abiraterone in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry
Srinivasa Reddy 1 Licto Thomas 1 Lokesh Ramanna 1 Arindam Mukhopadhyay 1 Saral Thangam 1
1 Norwich Clinical Services Pvt. Ltd., BA & MW, Bangalore, Karnataka, India
DOI : 10.23893/1307-2080.APS.05605 Viewed : 21074 - Downloaded : 10921 A LCMS/MS method for the determination of abiraterone in human plasma was described. After extraction of sample from plasma by LLE method it was dried and reconstituted in mobile phase. 20?L of sample was injected to a C18 column and eluted with a mobile phase (2 mM Ammonium formate, pH 3.5: Acetonitrile: 30:70, v/v) at a flow rate of 1.2 mL/min. MRM transitions were monitored as m/z 350.3 ? 156.1 (abiraterone) and m/z 354.3 ? 160.1 (abiraterone D4). Sample concentrations were calculated by linear regression analysis using the analyst software 1.5.1. An excellent linear response was obtained over the concentration ranges 0.20 ng/mL to 79.50 ng/mL. The intra-day and inter-day precision were within 14.4%. The assay accuracy was 91.35?105.05%. Mean recovery was 60.20% (2.84%) for abiraterone. The limit of detection was 0.052 ng/mL. The stability issue of abiraterone in plasma was also addressed. This method can be used for bioequivalence studies. Keywords : abiraterone, prostate cancer, LLE, LCMS/MS, validation

Istanbul Medipol University